Epidemiological prediction of global ankylosing spondylitis (Bekhterev disease) by 2030-ResearchAndMarkets.com

[ad_1]

This “Ankylosing Spondylitis (Bekterev’s Disease)-Epidemiological Forecast to 2030” Report has been added to ResearchAndMarkets.com provide.

The report provides an in-depth understanding of AS, the history and predictive epidemiology of the United States, and AS trends.

Ankylosing spondylitis (AS) disease understanding

Ankylosing spondylitis (AS), also known as Bechterew’s disease, is a common inflammatory rheumatic disease that affects the axial bones and causes characteristic inflammatory back pain, which may lead to structural and functional damage and decrease Quality of Life. The clinical features of this group include inflammatory back pain, asymmetric peripheral oligoarthritis (mainly lower extremities), enteritis, and specific organ involvement, such as anterior uveitis, psoriasis, and chronic inflammatory bowel disease. Aortic root involvement and conduction abnormalities are rare complications of AS. The impact of AS on men is greater than that on women. The general onset of AS usually occurs in young people between 17 and 45 years old. However, it may also affect children and older people (American Spondylitis Association).

AS is a spondyloarthropathy (SpA)-spondyloarthropathy is a series of related inflammatory rheumatic diseases, including reactive arthritis (RA), psoriatic arthritis (PsA), and inflammatory bowel disease ( IBD) related spondyloarthritis, undifferentiated spondyloarthritis (USpA) and possibly Whipple’s disease and Behcet’s disease-often associated with other spondyloarthritis, including ReA, PsA, ulcerative colitis (UC) and Crohn’s disease. It has also been found that such patients often have a family history of AS or another spondyloarthropathy. Axonal spondyloarthritis or axial SpA (axSpA) refers to a special form of spondyloarthritis in which the main symptom is inflammatory back pain. Axial SpA is further divided into two groups, namely Ankylosing Spondylitis (AS) and Non-radial Axial Spondylitis (nr-axSpA).

Epidemiological view of ankylosing spondylitis (AS)

The epidemiology of the diseases covered in the report provides historical and predictive epidemiology, according to the total prevalence of ankylosing spondylitis, the prevalence of ankylosing spondylitis, and the diagnosis of ankylosing spondylitis by gender Prevalence, the prevalence of ankylosing spondylitis diagnosed by age group, the prevalence of ankylosing spondylitis diagnosed in the United States from 2018 to 2030.

Detailed breakdown of the epidemiology of ankylosing spondylitis (AS)

  • The total prevalence of ankylosing spondylitis (AS) in the United States is expected to increase from 2018 to 2030. In the total epidemic of 1,300,971 cases, 556,688 cases will be diagnosed by 2020. The compound annual growth rate of this case is expected to be (CAGR). During the 2018-2030 study period, it was 0.97%.

  • The prevalence of ankylosing spondylitis (AS) shows that men are dominant. By 2020, of the 556,688 confirmed cases in the United States, men and women have contributed 389,681 and 167,006 cases, respectively.

  • In the epidemiological model, different age groups are included, namely 18-29 years old, 30-39 years old, 40-49 years old, 50-59 years old, 60-69 years old and 70+ years old. It is estimated that the most prevalent age group of AS in the United States is 40-49 years old in 2020, accounting for nearly 150,306 of the total number of AS epidemic cases.

The diagnosis of ankylosing spondylitis is difficult to find because many people have low back pain-this is the main symptom. In addition, there is no specific laboratory test to determine ankylosing spondylitis. All these factors play an important role in the low diagnosis of AS. Due to the increase in progress, it is estimated that the diagnosis rate may increase in the next few years.

Report scope

  • The report covers a descriptive overview of AS, explaining the causes, symptoms, pathophysiology, and genetic basis of AS.

  • The report provides insight into the historical and predictive patient pool covering the United States.

  • The report assessed the risk and burden of disease and highlighted the unmet needs of the United States.

  • The report helps to recognize the growth opportunities in the United States for the patient population.

  • The report is based on the total prevalence of ankylosing spondylitis, the prevalence of diagnosed ankylosing spondylitis, the prevalence of ankylosing spondylitis diagnosed by sex, and the prevalence of ankylosing spondylitis diagnosed by age And gene-specific prevalence breaks down the epidemiology of diseases in the United States. Ankylosing spondylitis.

Reasons to buy

The AS report will allow users to:

  • Formulate business strategies by understanding trend shaping and driving the American AS epidemiological forecast.

  • The AS epidemiological report and model were written and developed by Masters and Ph.D. First-level epidemiologist.

  • The developed AS epidemiology model is easy to navigate, interact with dashboards and epidemiology based on a transparent and consistent methodology. In addition, the model supports the data provided in the report and uses reputable data sources to show disease trends during the 10-year forecast period.

Key topics covered:

1 key insights

2 Executive Summary of Ankylosing Spondylitis (AS)

3 Disease background and overview: ankylosing spondylitis (AS)

4 case reports

5 patient journey

6 Epidemiology and number of patients

7 appendix

8 publisher functions

9 Disclaimer

10About the publisher

For more information about this report, please visit https://www.researchandmarkets.com/r/gonh67

[ad_2]

Source link